2023 clinical immunization safety assessment (cisa) base IDIQ

Active Awarded Last action

Contract number
75D30123D18250
Awardee
Awarding agency
Task orders
3 $1,890,011 obligated

Award facts

Opportunity
  • 75D30123R72847 Solicitation number
Combined order value
  • $1,893,897 Current, with exercised options
  • $1,980,798 Potential, with all options
Last date to order 61% complete
IDV ceiling 2% used
$86,008,000.12
Maximum order
$86,008,000.12
Award type
Multiple award
Who can order
Only the awarding agency
NAICS code
611210 Junior Colleges
Set-aside
No set-aside
Competition
Full and Open Competition · 10 offers Negotiated Proposal / Quote
Pricing
Cost No Fee

Award details come from SAM.gov/FPDS.

About this IDV

The Centers for Disease Control and Prevention awarded an indefinite-delivery contract to Kaiser Foundation Hospitals with a ceiling of $86,008,000.12 on September 27, 2023, designated as the Clinical Immunization Safety Assessment (CISA) Base IDIQ through September 25, 2028. This is a multiple-award vehicle with no set-aside applied.

Place of performance spans Oakland, California and Durham, North Carolina, supporting Kaiser Permanente's role as a contributing research site in CDC immunization safety surveillance and clinical vaccine evaluation. The contract supports epidemiological research, vaccine safety assessments, and clinical studies grounded in Kaiser Permanente's integrated healthcare system and comprehensive electronic health records.

The base period runs through September 27, 2028, with options to extend the performance term. Under this IDIQ, Kaiser Foundation Hospitals has received at least two delivery orders priced on a cost-no-fee basis: the CISA RSV Infants Study with a ceiling of $741,949 (performance through September 26, 2027, performance location Durham, North Carolina) and a $239,339 delivery order issued September 28, 2023 (performance location Oakland, California). Both orders support immunization safety research priorities aligned with EO 14398.

Kaiser Permanente operates as a non-profit integrated healthcare system and research organization with no SBA set-aside designations. The organization delivers federal research services centered on health services research, epidemiological analysis, and clinical outcomes evaluation leveraging diverse patient populations and established research infrastructure.

Task orders

Task order Ordering agency Obligated Awarded
Home cisa laiv study - contributing site EO 14398 75D30126F00003 CDC Pittsburgh $981,237
Cisa RSV infants study (contributing site) 75D30124F00002 CDC Pittsburgh $730,098
2023 clinical immunization safety assessment (cisa) base IDIQ 75D30123F00001 CDC Pittsburgh $178,676

Transactions

Action Obligated Date
Other Administrative Action P00001 · EO 14398 $0
Original award $0

Quick answers

Who was awarded contract 75D30123D18250?

75D30123D18250 was awarded to Kaiser Foundation Hospitals by CDC Pittsburgh (Centers for Disease Control and Prevention) on September 27, 2023.

How much is contract 75D30123D18250 worth?

Orders under 75D30123D18250 have obligated $1,890,011. Their combined current value, with exercised options, is $1,893,897. Their combined potential value, with all options, is $1,980,798. 75D30123D18250's own ceiling is $86,008,000. A single order can be worth up to $86,008,000.

How many orders have been placed under contract 75D30123D18250?

3 orders have been placed under 75D30123D18250, the latest on September 25, 2026.

Who can order from contract 75D30123D18250?

75D30123D18250 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75D30123D18250 part of a contract vehicle?

Yes. 75D30123D18250 is part of Clinical Immunization Safety Assessment 2023 - 2028 (CISA).

Was contract 75D30123D18250 competed?

The extent of competition for 75D30123D18250 was full and open competition. The government received 10 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV